Moreover, these putative CSCs, such as those in pancreatic cancer (ALDH+ cells), colon cancer (CD133+ cells), breast cancer (CD44 + CD24− cells), and GC (CD44+ cells) are sensitive to Hh inhibitors [60–63]. This evidence concerns the gene CD44 and malignant colon neoplasm.